News

The safety and efficacy of Xanamem is currently being studied in clinical trials. Xanamem is not approved for use by the US Food & Drug Administration or any other regulatory authority.

14 Sep 2023	Actinogen	Video interview: [14.46 mins] Xanamem program update
31 Aug 2023	Media	Webcast video recording: Actinogen neuroscience webinar
07 Jun 2023	PR Newswire	Actinogen to present progress on Cognitive Impairment in Depression and Alzheimer’s Disease Phase 2 trials at the BIO International Convention
05 Jun 2023	Media	Insight: Beyond the amyloid hypothesis – how small molecules are giving hope to Alzheimer’s research
31 May 2023	PR Newswire	Actinogen to present progress on Cognitive Impairment in Depression and Alzheimer’s Disease Phase 2 trials at the BIO International Convention
24 May 2023	Actinogen	Webcast video recording: Actinogen Clinical Trials Science Forum 2023
30 Mar 2023	PR Newswire	Actinogen presents positive Phase 2a Xanamem data at AD/PD™ Alzheimer’s and Parkinson’s diseases conference
30 Mar 2023	Actinogen	Oral presentation: CMO presentation at Alzheimer’s and Parkinson’s Disease Conference (AD/PD™) in Gothenburg, Sweden
01 Mar 2023	Biotech Daily	Actinogen Appoints Nicki Vasquez Non-Executive Director
24 Feb 2023	Actinogen	Company presentation: Spark Plus Biotech Conference in Singapore
01 Feb 2023	Biotech Daily	Actinogen Appoints Dr Dana Hilt CMO
09 Jan 2023	Actinogen	Company presentation: Sachs Neuroscience Innovation Forum and other meetings during the JP Morgan Healthcare Conference week